An anti-CD18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48-hour reperfusion  by Arai, Masazumi et al.
1278 JACC Vol. 27, No. 5 
April 1996:1278-85 
An Anti-CD18 Antibody Limits Infarct Size and Preserves Left 
Ventricular Function in Dogs With Ischemia and 48-Hour Reperfusion 
MASAZUMI  ARAI,  MD, DAVID J. LEFER, PHD, TAKEHIKO SO, MD, ANTHONY DIPAULA, BS, 
THOMAS AVERSANO,  MD, LEWIS C. BECKER, MD, FACC 
Baltimore, Maryland 
Objectives. This study investigated whether an antibody against 
neutrophil adhesion protein CD18 could limit myocardial infarct 
size and preserve left ventricular function after prolonged reper- 
fusion in a canine model. 
Background. Myocardial reperfusion injury is mediated in part 
by accumulation of activated neutrophils. Although antibodies 
against CD18 have been shown to reduce neutrophil influx and 
infarct size after ischemia and 3 to 4 h of reperfusion, it is 
unknown whether protection is sustained beyond this time or 
whether there is meaningful preservation of ventricular function. 
Methods. Dogs undergoing 90-min circumflex coronary artery 
occlusion and 48-h reperfusion were randomized to receive 
1 mg/kg bodyweight of R15.7 (an anti-CD18 antibody, n = 12) or 
saline (control, n = 12) 10 rain before reperfusion. Contrast left 
ventriculography was used to measure left ventricular ejection 
fraction and regional chord shortening at baseline, during occlu- 
sion and at 48 h. Microspheres injected during occlusion were 
used to measure collateral flow and risk region size. Postmortem 
infarct size was measured with triphenyltetrazolium chloride. 
Results. In the dose administered, R15.7 bound to neutrophils 
in vivo, with >85% saturation of CD18 for >24 h, with sustained 
antibody excess in the plasma. R15.7 significantly reduced infarct 
size after adjusting for the effect of collateral flow (p = 0.0002, 
analysis of covariance). In a subgroup of dogs with collateral flow 
<30% of nonischemic flow, infarct size was reduced from 34.6 "4- 
3.9% (mean -+ SE) of the region at risk in the control group to 
19.5 -+ 3.3% in the antibody group (p = 0.008). Ejection fraction 
and regional chord shortening did not differ between the two 
groups at baseline or during occlusion, but after 48-h reperfusion, 
ejection fraction and inferior wall regional cord shortening (rep- 
resenting the infarct zone) were both higher in the R15.7 group 
than the control group (43.6 -+ 2.9% vs. 28.5 +-- 1.8%, p < 0.01; 
2.55 -+ 0.29% vs. 1.06 + 0.18%, p < 0.05). 
Conclusions. A single injection of an anti-CD18 antibody given 
before reperfusion can limit myocardial infarct size by nearly 50% 
and preserve global and regional left ventricular function after 
48 h of reperfusion. 
(J Am CoU Cardiol 1996;27:1278-85) 
Neutrophils are believed to be causally related to reperfusion 
injury of various organs, including the heart, intestine and lung 
(1-3). Inhibition of neutrophils by drugs (4) or removal by 
filtration (5) significantly reduces reperfusion injury of the 
heart. Adherence of neutrophils to vascular endothelium is
believed to represent an essential first step in the process of 
neutrophil transmigration a d influx into injured myocardium 
(6). Although initial attachment of neutrophils to vascular 
endothelium is thought to be mediated by molecules belonging 
to the selectin family, the CDll/CD18 integrins are primarily 
responsible for tight cellular adhesion, diapedesis out of the 
vascular lumen, chemotaxis, phagocytosis and adherence- 
related oxidant production (6,7-11). 
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Anti-CD18 monoclonal antibodies have been reported to 
reduce organ injury and improve survival from hemorrhagic 
shock (12) and prevent reperfusion-induced lung (13) and 
intestinal vascular injury (2). Anti-CD18 antibodies have also 
been shown to reduce short-term yocardial reperfusion i - 
jury in some studies (14-17), although not all have reported 
efficacy (18). There are important gaps in the current body of 
knowledge concerning anti-CD18 antibodies and reperfusion 
injury. Most previous tudies have used short-term reperfusion 
lasting only a few hours. It is therefore possible that these 
antibodies merely delay the appearance of lethal myocardial 
injury during reperfusion rather than produce atrue reduction 
in infarct size. In addition, no study has examined the effect of 
antibody treatment on left ventricular function. It is therefore 
unknown whether the reduction in infarct size observed in 
previous tudies would be translated into a meaningful im- 
provement in cardiac function. 
Our study was done to determine the maximal benefit hat 
could be achieved with an anti-CD18 antibody in a canine 
model of myocardial ischemia nd prolonged reperfusion. An 
anti-CD18 antibody, R15.7, was selected that had been shown 
(9,10) to effectively inhibit adherence-related functions of 
canine neutrophils invitro. A dose was chosen that resulted in 
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>85% saturation of CD18 receptors and excess circulating 
antibody for >24 h. Reperfusion was carried out for 48 h after 
90-min ischemia to ensure completion of the infarction, and 
global and regional eft ventricular function were measured 
serially by contrast left ventriculography. 
Methods  
Experimental animals. Adult mongrel male and female 
dogs weighing 16 to 27 kg were used for these studies. All 
experiments were performed in accordance with the guiding 
principles of the American Physiological Society. All animals 
were vaccinated for common viral infections, dewormed and 
observed for 2 weeks to rule out acute illness. All had negative 
test results for heartworm infection. 
Surgical preparation. Dogs were anesthetized with 
30 mg/kg body weight of sodium pentobarbital nd mechani- 
cally ventilated with room air. All surgical procedures were 
performed aseptically, including aseptic preparation of the skin 
and use of sterile surgical drapes and instruments and wearing 
of surgical masks and sterile gloves. After left thoracotomy was 
performed in the fifth intercostal space, a mechanical snare 
(formed by passing a suture through a length of plastic tubing, 
n = 18) or an inflatable cuff occluder (n = 25) was placed 
loosely around the left circumflex coronary artery either prox- 
imal or distal to the first large marginal branch, depending on 
the size of the branch, to achieve a moderate-sized ischemic 
territory. The proximal end of the occluder was exteriorized 
through the chest wall, the thoracotomy incision was closed, 
and air was evacuated from the chest. Polyethylene catheters 
were placed in the femoral veins for antibody administration 
and blood sampling, and an 8F sheath was placed in the 
femoral artery (extending into the descending aorta) for blood 
pressure monitoring and reference blood sampling for blood 
flow measurements. After instrumentation, the dogs were 
moved to a different room for cineangiography and fixed in a 
plastic cradle to maintain constant position. A 6F or 7F pigtail 
catheter was inserted into the left ventricle through the 
femoral artery sheath for injection of radiolabeled micro- 
spheres and contrast medium. 
Experimental protocol. After the chest was closed, dogs 
underwent circumflex coronary artery occlusion for 90 min 
followed by 48 h of reperfusion. Aortic blood pressure, heart 
rate and standard limb lead electrocardiogram (ECG) were 
monitored continuously. Ten minutes before reperfusion, by 
random selection, R15.7 (1 mg/kg) or an equivalent volume of 
saline was given intravenously over 1 min. To confirm in vivo 
antibody binding to neutrophils, serial blood samples were 
withdrawn for flow cytometry from dogs in the R15.7 group 
before and 10 min, 20 rain, 1 h, 3.5 h, 24 h and 48 h after 
antibody injection. Hemodynamic variables were recorded 
before and 5, 70 and 90 min after occlusion and 10 min, 1 h and 
3.5 h after reperfusion. Myocardial blood flow measurements 
were made before and after 75 min of coronary occlusion and 
at 10 min and 3.5 h of reperfusion. 
After 3.5 h of reperfusion, all catheters were removed, the 
femoral artery and vein were ligated, and the dogs were 
allowed to recover from anesthesia. Forty-eight hours after 
reperfusion, the dogs were reanesthetized with sodium pento- 
barbital and mechanically ventilated, and a catheter was rein- 
serted into the aorta and left ventricle through the other 
femoral artery. After acquisition of blood samples and hemo- 
dynamic data and measurement of myocardial blood flow, the 
chest was opened and the heart excised. 
Monoclonal antibody. The murine monoclonal antibody 
R15.7, an immunoglobulin G1 that recognizes a functional 
epitope on CD18 on both human and dog neutrophils (10) was 
obtained as a gift from Dr. Robert Rothlein, Boehringer- 
Ingelheim Pharmaceuticals. The antibody concentration was 
12.17 mg/ml, and the solution contained <1 endotoxin 
units/mg of endotoxin. 
In vivo antibody binding to neutrophils. To confirm in vivo 
antibody binding to neutrophils, whole-blood samples with- 
drawn at each time point were incubated with a saturating 
concentration of fluorescein-conjugated goat anti-mouse im- 
munoglobulin (Tago Inc.) for 30 min at 4°C and then washed 
with phosphate-buffered saline containing 0.2% bovine serum 
albumin to remove unbound antibody. Neutrophil isolation 
was accomplished by erythrocyte lysis using whole-blood lysing 
reagent (Coulter Immunology) and the cells were fixed in 1% 
paraformaldehyde. Antibody binding was then determined by 
flow cytometry (Coulter EPICS ELITE, Coulter Immunology), 
and fluorescence intensity was used as a quantitative measure 
of binding. In addition, to assess the saturation of R15.7 
binding sites on circulating neutrophils, a second aliquot of 
whole blood at each time point was incubated with a saturating 
concentration of R15.7 (20/zg/ml) for 30 min at 4°C, and the 
difference in fluorescence intensity was recorded. 
Regional blood flow measurement. Radioactive micro- 
spheres (DuPont), 15 /zm in diameter and labeled with 
gadolinium-153, tin-ll3, ruthenium-103, niobium-95 or 
scandium-46, were used to measure myocardial blood flow 
(19). Microspheres (2 x 106) were injected into the left 
ventricle through the pigtail catheter, and a simultaneous 
reference blood sample was withdrawn from the arterial 
sheath. After excision of the heart, tissue samples were ob- 
tained and counted in a scintillation counter, along with 
radioactive standards and background and reference blood 
samples. Regional myocardial blood flow was calculated by 
standard methods (19). Mean flows (ml/min per g) to the inner 
two-fifths, middle one-fifth and outer two-fifths of the left 
ventricular wall within the ischemic-reperfused r gion and to 
the opposite nonischemic region were determined at each time 
point. Samples located at the border between ischemic and 
nonischemic areas were not included in this analysis. 
Assessment of infarct, risk and no-reflow areas. The left 
ventricle was sectioned into five slices parallel to the atrioven- 
tricular ing. After excision of the right ventricle, each slice was 
weighed, incubated in a 2% solution of triphenyltetrazolium 
chloride (TTC) for 30 rain at 37°C to visualize the infarct area 
and photographed. Area at risk was assessed by the regional 
blood flow data according to the following method. Contiguous 
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strips, 3 to 6 mm wide and 2 to 3 mm deep, were excised from 
the basal surface of each left ventricular slice, extending from 
the endocardial tothe epicardial surface and encompassing the 
entire ischemic ircumflex region (8 to 11 strips were usually 
sufficient). One strip was taken from the nonischemic region in 
each left ventricular slice. Each strip was then divided into five 
equal samples (0.05 to 0.2 g), and each was weighed and 
analyzed for regional flow. Flow to nonischemic myocardium 
was calculated by averaging all the nonischemic flow values 
over all the left ventricular slices at each time point. Samples 
from the circumflex artery territory were considered "isch- 
emic" (and therefore within the region at risk) if the flow 
during coronary artery occlusion was <50% of the nonisch- 
emic value. Samples were classified as having "no reflow" if the 
flow at 48 h of reperfusion was <50% of nonischemic flow. 
These criteria have been defined in previous tudies from our 
laboratory (20,21). 
The location of each myocardial strip was marked by a 
scalpel incision on each left ventricular slice before photogra- 
phy. Subsequently, the photographic transparencies were pro- 
jected, and the epicardial and endocardial edges, the infarct 
area (TTC negative) and the locations of the tissue samples 
were traced. Each sample that met the definition of "ischemic" 
or "no-reflow," or both, was color coded. The areas of the 
ischemic risk region, no-reflow region and the infarcted myo- 
cardium were determined by computerized planimetry of the 
tracings. Infarct and no-reflow region sizes were then calcu- 
lated by summing the values for each left ventricular slice (the 
no-flow region was included in the infarct region) and ex- 
pressed as a fraction of the risk region or left ventricular for 
each heart. The amount of infarct hemorrhage was judged 
from the color transparencies for each left ventricular slice 
using a four-point scale (0 = none; 1 = mild; 2 = moderate; 
3 = severe), without knowledge of group assignment. A score 
was calculated for each dog by averaging the scores of the five 
left ventricular slices. 
Left ventrieulography. Left ventriculography was per- 
formed at baseline, during coronary occlusion and 10 min and 
48 h after reperfusion. Omnipaque 350 (iohexol, Sanofi 
Winthrop) was injected into the left ventricle at 7 ml/s for 4 s, 
and 20 ° right anterior oblique images were recorded at 30 
frames/s, and a calibration grid was filmed at heart level 
immediately afterward. Ventriculograms were technically ad- 
equate for analysis in 10 of 12 control dogs and in all 12 
antibody-treated dogs. The developed cine films were pro- 
jected, and a pair of maximally contrast-enhanced end- 
diastolic and end-systolic mages were selected. These images 
were digitized and analyzed with an ImageComm System 
equipped with a 512 x 512 high resolution monitor. Using 
software available with the system, the end-diastolic and 
end-systolic outlines of the left ventricle were drawn manually, 
excluding the papillary muscles. Ejection fraction was calcu- 
lated by the area-length method, assuming aprolate spheroid 
shape of the left ventricle (22). The end-diastolic volume was 
determined using the filmed grid for calibration and the 
single-plane modification of the Sandier-Dodge area-length 
method (22). Using the centerline method, 100 chords were 
automatically generated around the perimeter, and the short- 
ening of each chord was expressed as a fraction of the 
perimeter length (23). The left ventricle was divided into five 
regions of 20 chords each (anterobasal, midanterior, apex, 
midinferior, inferobasal), and the shortening of each of these 
regions was expressed by the shortening of the center chord 
within that region. Regional anterior wall motion represented 
the average of the central chord shortening for the anterobasal 
and midanterior regions, whereas inferior wall motion repre- 
sented the average of the inferobasal and midinferior regions. 
Myeloperoxidase assay. Transmural myocardial samples 
weighing 0.5 to 1.0 g were taken from both the central portion 
of the area at risk and the normal area of a midventricular 
slice. The samples were frozen immediately after counting 
microsphere activity and stored at -20°C. The activity of 
myeloperoxidase, an index of neutrophil accumulation, was 
measured as previously described (24). Results were expressed 
as units of myeloperoxidase/100 mg wet tissue weight. 
Statistical analysis. Hematologic and hemodynamic vari- 
ables during ischemia nd reperfusion i  control and R15.7 
groups were compared by repeated measures analysis of 
variance. Two-way analysis of variance, combined with Dun- 
nett's post hoc test for multiple comparisons, was used to test 
for an overall difference between groups in each variable, and 
for differences at each time point within and between groups. 
Comparisons of infarct size and tissue myeloperoxidase activity 
were made by the Student t test. The relation between infarct 
size (percent of risk region) and collateral blood flow was 
determined by linear regression analysis, and analysis of co- 
variance was used to determine the significance of the treat- 
ment effect and the relation between i farct size and collateral 
blood flow. All results are reported as mean value _ SE. 
Results 
Forty-one dogs survived until the time of randomization to 
R15.7 or saline (10 min before reperfusion). Of these, five dogs 
in the control group and four in the R15.7 antibody group died 
before completion of the experiment. Eight additional dogs 
were eliminated because of a technical failure of the coronary 
occlusive device, whereby occlusion or release did not occur 
properly. This group included three dogs with a mechanical 
snare occluder (two control group, one R15.7 group) that 
failed to reperfuse on the basis of microsphere flow measure- 
ments. In two of these dogs, flow did not increase at all from 
occlusion to 10 min of reperfusion, whereas in the third, it 
increased only 25% and then fell to 40% below occlusion 
values at 3.5 h of reperfusion. Two dogs (one control group, 
one R15.7 group) were ischemic at baseline (flow <20% of the 
nonischemic value), apparently related to premature closure of 
the occluder. Three dogs (all control group) with a balloon 
occluder were eliminated because of balloon rupture and 
unsuccessful coronary artery occlusion. The remaining 24 
animals (12 control group, 12 antibody group) form the basis of 
this report. 
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Antibody binding to circulating neutrophils. Blood sam- 
ples from four dogs in the antibody group were analyzed by 
indirect flow cytometry. Mean channel fluorescence for neu- 
trophils isolated before R15.7 injection was 3.2 _+ 0.4 and 
increased to 205.7 _+ 7.6 at 10 rain after injection, indicating 
significant R15.7 binding to neutrophils. Saturation of R15.7 
binding sites averaged 86.6 _+ 7.6% at the time of reperfusion 
(10 rain after injection) and 88.4 _+ 11.7%, 95.2 _+ 4.8%, 92.2 _+ 
1.8% and 62.6 _+ 30.3% at 1, 3.5, 24 and 48 h of reperfusion, 
respectively. 
Hemodynamic variables. During coronary artery occlu- 
sion, systolic, diastolic and mean blood pressures decreased in
both control and antibody groups but recovered to baseline by 
3.5 h of reperfusion. Heart rate did not change significantly. 
Overall, the antibody and control groups did not differ signif- 
icantly in any hemodynamic variable. Diastolic and mean 
blood pressures were slightly lower in the antibody group than 
the control group during occlusion (62 _+ 4 vs. 71 _+ 2 mm Hg, 
72 -+ 4 vs. 82 _+ 2 mm Hg, respectively, at70 rain of occlusion, 
both p < 0.05), but otherwise there were no significant 
differences between the two groups. Antibody injection pro- 
duced no measurable hemodynamic effect. 
Hematologic variables. Overall, significant differences oc- 
curred between antibody and control groups in leukocyte 
count (p < 0.0001), neutrophil count (p = 0.0006) and 
hematocrit (p = 0.0065). During coronary occlusion and the 
first 3.5 h of reperfusion, the following changes were recorded. 
Leukocyte and neutrophil counts were increased inthe control 
group at 3.5 h of reperfusion; hematocrit was increased slightly 
during occlusion and at 10 rain of reperfusion i the antibody 
group; and platelet count increased in both groups during 
occlusion and the first hour of reperfusion. There were no 
significant differences between the two groups during the first 
3.5 h of reperfusion. After 3.5 h of reperfusion, leukocyte and 
neutrophil counts increased at 24 and 48 h of reperfusion i
both groups, but significantly more so in the antibody group at 
the 24-h time point (36,700 _+ 900 vs. 25,300 _+ 2,300 leuko- 
cytes//zl; 32,600 _+ 3,100 vs. 23,300 + 2,200 neutrophils/pJ, both 
p < 0.05). Hematocrit and platelet count were reduced below 
baseline levels at 48 h of reperfusion i both groups, but there 
were no significant differences between groups. 
Regional myocardial blood flow. Myocardial blood flow to 
the inner two-fifths, mid one-fifth, and outer two-fifths of the 
left ventricular wall within the ischemic-reperfused r gion is 
shown in Table 1. Blood flow decreased inboth groups during 
coronary artery occlusion to -6% of nonischemic flow in the 
endocardium and 30% in the epicardium. At 10 rain of 
reperfusion, hyperemia occurred in all layers, although the 
increase in the endocardium tended to be less than the other 
layers. At 3.5 h of reperfusion, flow decreased and was below 
baseline levels in the endocardium at both 3.5 and 48 h of 
reperfusion (p = NS). There were no significant overall 
differences between the control and antibody groups, nor were 
there any significant differences in any of the left ventricular 
layers at any time point during the experiment. Similarly, flow 
Table 1. Myocardial B ood Flow (ml/min per 100 g) in Control and 
Antibody Groups 
Reperfusion 
Region Baseline Occlusion 10 rain 3.5 h 48 h 
Ischemic-reperfused 
Endocardium 
Control group 72 _+ 8 5 _+ 1" 
Antibody group 70 _+ 10 3 _+ 1' 
Midcardium 
Control group 58 _+ 7 11 _+ 2* 
Antibody group 59 _+ 7 8 _+ 2* 
Epicardium 
Control group 55 + 6 25 _+ 3? 
Antibody group 55 _+ 8 19 __ 4# 
Nonischemic 
Yransmural 
Control group 66 _+ 8 68 _+ 8 
Antibody group 68 _+ 10 67 _+ 6 
111_+26" 53_+7 55_+8 
82_+18 51_+6 42_+5 
127 _+ 20* 54 _+ 5 86 _+ 13t 
122_+24' 60_+8 61_+5 
113-+16' 66 +4 81+12 
108_+20 * 69_+9 58_+6 
63 + 9 82 + 6 117 -+ 13' 
70-+7 86-+11 85-+8~: 
*p < 0.01, tp < 0.05 versus baseline in same group. :I:p < 0.05 versus control 
group at same time point. Data presented are mean value _+ SE. 
in the nonischemic region did not change significantly during 
the experiment and did not differ between the two groups. 
Infarct size. Figure 1 shows a representative mid-left ven- 
tricular slice from a dog in the control group and a comparative 
dog in the antibody group. The two dogs were selected to have 
a similar-sized area at risk (27.4% vs. 26.2% of the left 
ventricle, respectively) and similar ischemic severity (transmu- 
ral collateral flow 0.11 ml/min per g in both). Infarct size was 
52% of the area at risk in the control dog but only 17.2% of the 
area at risk in the dog treated with R15.7. 
Infarct size was inversely related to collateral blood flow in 
both groups (Fig. 2), and the regression line for the antibody 
group (y = 29.6 - 0.67x, r = 0.67) was displaced ownward in 
a parallel manner compared with that for the control group 
(y = 49.4 - 0.90x, r = 0.88). The contribution of antibody 
treatment and collateral flow to infarct size were determined 
by analysis of covariance using a dummy variable for the 
treatment group. The effect of treatment was significant (p = 
0.0002), after adjusting for flow. A significant protective ffect 
of antibody treatment was also observed when epicardial or 
endocardial collateral 
used (p = 0.0024 for 
flow). 
Including all dogs, 
flow rather than transmural flow was 
epicardial flow, 0.016 for endocardial 
and without adjusting for flow, mean 
infarct size, expressed as a percent of the area of risk, was 
reduced in the antibody group (18.4 _+ 3.2%) compared with 
that in the control group (28.3 _+ 4.5%), but the difference was 
of borderline statistical significance (p < 0.09). Excluding dogs 
with collateral flow >30% of nonischemic ftow allowed better 
matching of the two groups for collateral f ow. In this subgroup 
(9 control group, 11 antibody group dogs), infarct size was 
19.5 _+ 3.3% of the risk region in the antibody group compared 
to 34.6 _+ 3.9% in the control group (p = 0.008) (Fig. 3). 
Transmural collateral flow was 14.2 _+ 2.0% of normal versus 
15.7 _+ 1.8%, and risk region was 23.1 + 2.7% of the left 
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Figure 1. Representative mid-left ventricu- 
lar slice from a dog in the control group and 
a comparative dog in the antibody group. 
The two dogs were selected to have a 
similar-sized area at risk (27.4% vs. 26.2% 
of the left ventricle) and a similar severity 
of isehemia (transmural collateral flow 
0.11 ml/min per g in both). Infarct size was 
52% of the area at risk in the control dog 
versus 17.2% in the antibody-treated dog. 
ventricle versus 23.4 +__ 3.1%, respectively, in this subgroup 
(neither difference statistically significant). The no-reflow area 
tended to be smaller in the antibody group, but the difference 
was not statistically significant (p = 0.16) (Fig. 3). This finding 
is consistent with the observation that antibody treatment did 
not attenuate the blood flow reduction at 48 h after reperfu- 
sion (Table 1). The infarct hemorrhage scores did not differ 
significantly between the antibody and control groups (1,3 + 
0.3 vs. 1.2 _ 0.2, respectively). 
Left ventricular function. Left ventricular ejection fraction 
in the antibody group was similar to that in the control group 
at baseline, during occlusion and at 10 rain of reperfusion; but 
at 48 h of reperfusion, ejection fraction was significantly higher 
in the antibody group than the control group (28.5 _+ 1.8% vs. 
43.6 _+ 2.9%, p < 0.01) (Fig. 4). Overall, ejection fraction 
differed significantly between the two groups by two-way 
analysis of variance (p -=- 0.012). End-diastolic volumes at 48 h 
of reperfusion were similar in the control and antibody groups 
Figure 2. Relation between i farct size and severity of ischemia nthe 
control and antibody groups. The relation for the antibody group is 
shifted significantly downward (p = 0.0002). 
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(60 + 5 vs. 57 _+ 2 ml, respectively). Concomitant with 
preservation of global left ventricular ejection fraction, re- 
gional wall motion in the inferior portion of the left ventricle 
(infarct zone) at 48 h of reperfusion was significantly higher in 
the antibody group than the control group (fractional shorten- 
ing 1.06 _+ 0.18% vs. 2.55 _+ 0.29%, p < 0.05) (Fig. 5). Non- 
ischemic anterior wall motion was similar in the two groups. 
Myocardial myeloperoxidase activity. Myeloperoxidase ac- 
tivity in transmural myocardial samples was measured to assess 
neutrophil accumulation at48 h of reperfusion. Myeloperoxi- 
dase activity was higher in ischemic-repeffused myocardium 
than in nonischemic myocardium in both groups (control 
group: 2.88 _ 1.0 vs. 0.15 +_ 0.09 U/100 mg, p < 0.05; antibody 
group: 1.23 +_ 0.28 vs. 0.11 +_ 0.07 U/100 rag, p < 0.01). 
Myeloperoxide activity in the ischemic-reperfused region 
tended to be lower in the antibody group, but the difference 
was not statistically significant (p = 0.095). 
Figure 3. Comparison of area at risk as a percent of left ventricle (LV) 
and infarct and no-reflow areas as a percent of area at risk. Dogs with 
collateral f ow >30% of normal were excluded from this analysis to 
provide better matching of collateral flow between the two groups. 
Bars = mean value + SE. 
s° 4 
40 
p<0.01 
I I 
? 
IV 
NS 
3 0 - [ - -1  
2o 
lO 
o 
Area at Risk 
LV 
T 
In farc t  Area 
Area at Risk 
[] Control (n=9) 
[] Ant ibody (n=l l )  
NS 
F - - I  
T 
No-Reflow Area 
Area at Risk 
JACC Vol. 27, No. 5 ARAI ET AL. 1283 
April 1996:1278-85 ANTI-CD18 ANTIBODY LIMITS MYOCARDIAL INJURY 
~. 70- 
.~ .~ 60-  
o 
g 
~7 
50 
40 
30 
20-  
Control (n=10) 
• Antibody (n=12) t~** 
~ t  
Base l ine  Occ lus ion  10ra in  48 'hr  
Reper fus ion  
Figure 4. Left ventricular ejection fraction i  the control and antibody 
groups. Left ventricular ejection fraction i  the antibody group was not 
significantly different from that in the control group at baseline, during 
occlusion and at 10 rain of reperfusion but was significantly higher at 
48 h of reperfusion. **p < 0.01 for control versus antibody group. #p < 
0.05, compared with baseline value in same group. Bars = mean 
value _+ SE. 
Discussion 
Although coronary reperfusion can salvage ischemic myo- 
cardium and limit the extent of infarction, there is increasing 
evidence that reperfusion can also result in lethal injury of 
myocytes that were injured but still viable at the time of 
reperfusion. Repeffusion i jury appears to be related, at least 
in part, to the development of postischemic inflammation, 
whereby activated neutrophils enter the reperfused myocar- 
dium, release high concentrations of oxidants and other 
injurious mediators or aggregate in the microvasculature to
produce further ischemia. Adherence of neutrophils to endo- 
thelial cells and matrix proteins is essential for these processes 
and is dependent on surface expression and activation of the 
CDI1/CD18 integrin complex. Our study demonstrates that a 
single injection of an anti-CD18 monoclonal ntibody before 
reperfusion, after 90 min of coronary artery occlusion, results 
in almost a 50% decrease in myocardial infarct size and a 
significant preservation of global and regional eft ventricular 
function measured 48 h later. To our knowledge, ours is the 
first study to document sustained myocardial protection in 
conjunction with a meaningful preservation of left ventricular 
function after treatment with an anti-CD18 antibody. 
Previous results with anti-CD18 antibodies. Several previ- 
ous studies have examined the ability of anti-CDll/CD18 
antibodies to limit myocardial infarct size in animal models of 
ischemia-reperfusion. Myocardial salvage has been reported 
after treatment with anti-CD18 antibodies before or during 
coronary artery occlusion in several small animal models 
(rabbits, ferrets and rats) reperfused for 5 to 48 h (15,16,25). 
When the antibody was given only before rcperfusion, a
considerably smaller effect was seen (16). Ma et al. (14) 
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Figure 5. Regional myocardial function in the control and antibody 
groups assessed by fractional chord shortening averaged for the 
anterior (control) and inferior (infarct) regions. The only significant 
difference between the control and antibody groups was seen in the 
inferior wall at 48 h of reperfusion. *p< 0.05, **p < 0.01 compared 
with baseline value in the same group. Bars = mean value _+ SE. 
reported that R15.7, the same antibody used in our study, 
produced aprofound reduction in myocardial infarct size and 
preservation of endotbelium-dependent vasoreactivity when 
given before reperfusion i cats with 1.5 h of ischemia followed 
by 4.5 h of reperfusion. However, collateral flow was not 
measured, making it difficult o be certain that the severity of 
ischemia in the treated and control groups was comparable. In 
contrast, Tanaka et al. (18) reported that F(ab')2 fragments of
the anti-CD18 antibody IB4, given both before coronary occlu- 
sion and after eperfusion, failed to modify infarct size in dogs 
with 90 rain of ischemia followed by 3 h of reperfusion, despite 
a considerable reduction of neutrophil accumulation i the 
infarct region. Studies from our own laboratory (17) showed 
that both R15.7 and MHM.23, another anti-CD18 antibody, 
can reduce infarct size in dogs with 90 min of ischemia 
followed by 3.5 h of reperfusion, but that MHM.23 was 
ineffective in animals with the most severe ischemia (collateral 
flow -<0.1 ml/min per g). None of these studies examining 
anti-CD18 antibodies measured the effect of treatment on left 
ventricular function. Other approaches producing putative 
neutrophil suppression, including F(ab')2 fragments of an 
anti-CDllb antibody (26), perfluorochemical (27) and adeno- 
sine (28), have resulted in sustained limitation of infarct size or 
preservation f left ventricular function, or both >24 to 72 h in 
canine models. 
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Properties of R15.7. Our study was done to determine the 
maximal sustained benefit that could be achieved in our 
experimental model using an anti-CD18 antibody to block 
adherence-related neutrophil functions. The antibody selected 
has been shown in vitro to effectively block adherence of 
canine neutrophils to cultured canine endothelial cells and 
maximally inhibit H20 2 release from canine neutrophils tim- 
ulated by platelet-activating factor (9,17). In addition, i mg/kg 
of R15.7 was shown (17) in vivo to produce antibody binding to 
>95% of circulating neutrophils, with >85% saturation of 
CD18 molecules, and neutrophil accumulation i  infarcted 
myocardiurn was reduced by 64%. In the present study, we 
demonstrated nearly complete saturation of CD18 receptors 
and sustained excess of circulating antibody for at least 24 h. 
Our data indicate that R15.7 is directed against a function- 
ally important epitope on CD18 and that it binds to this 
epitope with high affinity. Although R15.7 was raised against 
canine peritoneal macrophages and screened against human 
CD18, it also cross-reacts and is functional in the cat (14), cow 
(29), rabbit (30) and human (9), in addition to the dog, 
suggesting that the epitope for R15.7 is highly conserved 
among species. Amino acids 96 to 389 and those in the 
cytoplasmic domain are known to be 95% identical among 
human, murine and bovine CD18, although canine CD18 has 
not yet been sequenced (31). Other monoclonal antibodies 
raised against CD18 may not bind with as high an affinity, 
requiring higher or more frequent in vivo dosing, or both to 
saturate available CD18 binding sites, or may not bind to 
functionally important epitopes. Antibodies raised against 
porcine CD18 have been found to cross-react with antigens 
expressed on rat, mouse, hamster, abbit, dog, cow and human 
leukocytes, upporting the notion that CD18 contains everal 
highly conserved epitopes (32). 
Mechanisms of action of anti-CD18 antibodies. Although 
anti-CD18 antibodies can provide protection against myocar- 
dial reperfusion injury, it is not clear which of the several 
CD18-dependent eutrophil functions must be neutralized. 
Adherence of neutrophils to endothelial cells and matrix 
proteins, as well as other neutrophils, can be blocked by 
anti-CD18 antibodies in vitro. In vivo, these effects are thought 
to translate into reduced transmigration of activated neutro- 
phils into the reperfused myocardium, as well as improved 
microvascular perfusion. Perhaps even more important, im- 
paired adhesion can result in reduced release of oxygen 
radicals and other oxidants from stimulated neutrophils, po- 
tentially preventing oxidant-mediated myocyte death (9,17). Of 
course, anti-CD18 antibodies cannot inhibit those mechanisms 
of cell death that are independent of CD18, such as direct 
complement-mediated injury (through the membrane attack 
complex) or myocyte apoptosis. 
Potential adverse ffects of anti-CD18 antibodies. Inhibi- 
tion of neutrophil function by anti-CD18 antibodies could 
theoretically have adverse consequences because it represents 
a "sledgehammer" approach that interferes with all CD18- 
dependent cellular functions throughout he body. Even a 
single injection of a holoantibody like R15.7 would presumably 
inhibit these functions for up to 48 h. This inhibition could lead 
to increased susceptibility to infection and possibly to delayed 
healing of the infarct, with aneurysm formation (33). Although 
no apparent infections occurred in the present study, patients 
with leukocyte adhesion deficiency related to mutations in the 
CD18 protein are subject o recurrent infections, often fatal in 
childhood, and their neutrophils are unable to bind to and 
cross the endothelium at sites of infection (11). Pretreatment 
of mice with an anti-CD l lb antibody was reported to markedly 
increase mortality after inoculation with Listeria monocyto- 
genes (34), but other investigators have not found increased 
mortality or infectious complications in other models (35). 
Other approaches. Other approaches to preventing 
neutrophil-mediated r perfusion i jury that might more selec- 
tively inhibit those neutrophils targeting or being activated 
within the reperfused myocardium are currently being ex- 
plored. These include antibodies to intercellular adhesion 
molecule-1 (ICAM-1), the endothelial igand for CD18 
(26,36); antibodies or oligosaccharides to block P-selectin, a 
protein responsible for initial loose adhesion of neutrophils to 
reperfused endothelium (37); and inhibitors of neutrophil 
activation, including inhibitors of complement (38), leukotri- 
ene B4 (4) and platelet-activating factor (39). Although these 
approaches are of interest, it is unknown whether they will 
prove to be as efficacious as anti-CD18 antibodies, given the 
remarkable redundancy ofmechanisms that exist for activating 
and targeting neutrophils in vivo. 
We gratefully acknowledge the valuable assistance of Cynthia Siu, PhD in the 
statistical analyses and Christine G. Borkowski in the preparation of the 
manuscript. 
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